Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 911.5 Thousand USD | -79.56% |
| 2022 | 4.45 Million USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 747 Thousand USD | 0.0% |
| 2024 Q2 | 577 Thousand USD | 0.0% |
| 2023 Q3 | 1.07 Million USD | -12.88% |
| 2023 Q2 | 1.23 Million USD | -11.3% |
| 2023 FY | 911.5 Thousand USD | -79.56% |
| 2023 Q1 | 1.38 Million USD | -68.86% |
| 2023 Q4 | 911.5 Thousand USD | -15.05% |
| 2022 Q3 | 1.62 Million USD | -8.13% |
| 2022 Q2 | 1.77 Million USD | 1.33% |
| 2022 FY | 4.45 Million USD | 0.0% |
| 2022 Q1 | 1.74 Million USD | 0.0% |
| 2022 Q4 | 4.45 Million USD | 174.17% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | 18.843% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 29.45% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 97.916% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -9015.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 91.192% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -570.221% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -657.677% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 89.513% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 98.135% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 75.653% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 96.791% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.397% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -316.212% |
| Molecular Templates, Inc. | 9.74 Million USD | 90.644% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 51.301% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 95.219% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 78.267% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.126% |
| Statera Biopharma, Inc. | 11.43 Million USD | 92.026% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -24.522% |
| Trevena, Inc. | 35.23 Million USD | 97.413% |
| Vaxxinity, Inc. | 13.26 Million USD | 93.127% |
| Vaccinex, Inc. | 26 Thousand USD | -3405.769% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |